Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co partners with Geisinger to improve adherence

Will use web application to decrease risk of diabetes and cardiovascular disease

Merck & Co is to team up with Geisinger Health System to improve patient adherence to diabetes and cardiovascular treatment plans using web applications and management solutions.

The US pharma company said the multi-year collaboration would improve patient health outcomes by facilitating shared decision making between patients and doctors.

It will do this by using a number of tools, including an interactive web application that's designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome - a group of several risk factors that increases the risk of someone developing type 2 diabetes and cardiovascular disease.

The application will initially be tested within Geisinger's own healthcare system, which serves more than 2.6m residents throughout 44 counties in central and northeastern Pennsylvania in the US, and uses electronic health records to keep track of patients' progress.

“When you have two leading healthcare companies that share a commitment to improve health outcomes and are focused on fundamental problems that have plagued the healthcare system for years, the results have the potential to be transformative," said Mark Timney, Merck's president of global human health, US.

Further care management programmes are in development, with the analytics of each scheme important to determine any expansion of the collaboration.

“We will closely monitor patient acceptance, treatment adherence, and other metrics to determine which tools and solutions have the ability to improve patient care and are ready to be deployed on a broader scale,” said Dr Glenn Steele, president and CEO of Geisinger Health System.

Adherence is becoming an increasing priority for pharma companies, healthcare systems and organisations as they look to ensure patients benefit as much from care plans and medicines as possible, but more can be done.

In September, 2011 several groups, including the European Federation of Pharmaceutical Industries and Associations (EFPIA), called for 'concrete EU-level action' to tackle a problem that they claimed led to 195,500 deaths in the region each year due to misdose and non-adherence.

19th June 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nascent Medical LLC

Nascent Medical is a global medical communications company partnering to deliver high quality market access, sales and medical science liaison...

Latest intelligence

A new reality for healthcare
When mobile phones came onto the mass market it would have been difficult to see how they were to develop into the ubiquitous multimedia devices they are now. Their power,...
Digital-green-grey.jpg
Are you getting these benefits from your digital technology?
Your organisation switched from ‘paper to glass’, buying the latest mobile devices and hiring digital agencies to fill them with eye-catching content. But what happened?...
Alzheimer's: the numbers we cannot forget
In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Infographics